The estimated Net Worth of Thomas W. Dubensky is at least $928 Thousand dollars as of 10 August 2017. Thomas Dubensky owns over 50,000 units of HTG Molecular Diagnostics Inc stock worth over $23,514 and over the last 9 years Thomas sold HTGM stock worth over $904,499.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Thomas Dubensky HTGM stock SEC Form 4 insiders trading
Thomas has made over 25 trades of the HTG Molecular Diagnostics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Thomas exercised 50,000 units of HTGM stock worth $50,000 on 10 August 2017.
The largest trade Thomas's ever made was exercising 144,301 units of HTG Molecular Diagnostics Inc stock on 1 June 2017 worth over $75,037. On average, Thomas trades about 21,420 units every 19 days since 2015. As of 10 August 2017 Thomas still owns at least 48,988 units of HTG Molecular Diagnostics Inc stock.
You can see the complete history of Thomas Dubensky stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Thomas Dubensky's mailing address?
Thomas's mailing address filed with the SEC is C/O HTG MOLECULAR DIAGNOSTICS, INC., 3430 E. GLOBAL LOOP, TUCSCON, AZ, 85706.
Insiders trading at HTG Molecular Diagnostics Inc
Over the last 10 years, insiders at HTG Molecular Diagnostics Inc have traded over $5,630,772 worth of HTG Molecular Diagnostics Inc stock and bought 1,019,150 units worth $14,128,765 . The most active insiders traders include Plc Gsk, Holdings A/S Novo, and Laurence W Lytton. On average, HTG Molecular Diagnostics Inc executives and independent directors trade stock every 64 days with the average trade being worth of $28,039. The most recent stock trade was executed by Stephen Barat on 8 June 2023, trading 888 units of HTGM stock currently worth $710.
What does HTG Molecular Diagnostics Inc do?
about htg molecular diagnostics: headquartered in tucson, arizona, htg's mission is to empower precision medicine at the local level. in 2013 the company commercialized its htg edge instrument platform and a portfolio of rna assays that leverage htg's proprietary nuclease protection chemistry. htg's product offerings have since expanded to include its htg edgeseq product line, which automates sample and targeted library preparation for next-generation sequencing. additional information is available at www.htgmolecular.com.
What does HTG Molecular Diagnostics Inc's logo look like?
Complete history of Thomas Dubensky stock trades at Aduro BioTech and HTG Molecular Diagnostics Inc
HTG Molecular Diagnostics Inc executives and stock owners
HTG Molecular Diagnostics Inc executives and other stock owners filed with the SEC include:
-
John Lubniewski,
President, Chief Executive Officer, Director -
John L. Lubniewski,
Pres, CEO & Director -
Shaun D. McMeans,
Sr. VP, CFO, Sec. & Treasurer -
Shaun McMeans,
Chief Financial Officer, Senior Vice President, Treasurer, Secretary -
Byron T. Lawson,
Sr. VP & Chief Commercial Officer -
Timothy Johnson,
Executive Chairman of the Board -
Byron Lawson,
Senior Vice President and Chief Commercial Financial Officer -
Lee McCracken,
Independent Director -
James LaFrance,
Independent Director -
Donnie Hardison,
Independent Director -
Michelle Griffin,
Independent Director -
Harry George,
Independent Director -
Ann Hanham,
Lead Independent Director -
Laura Beggrow,
Pres of Diagnostics -
Dr. Stephen A. Barat Ph.D.,
Sr. VP of Therapeutics -
Dr. Marian Navratil Ph.D.,
Sr. VP of R&D -
Dr. Patrick C. Roche,
Sr. VP of R&D -
Dr. Debra A. Gordon,
Sr. VP & Chief Legal Counsel -
Laura Lee Godlewski,
Sr. VP of Fin. & Admin. -
Dr. Maureen T. Cronin Ph.D.,
Sr. VP & Chief Scientific Officer -
Christopher P Kiritsy,
Director -
Stephen Barat,
Senior VP of Therapeutics -
Debra A Gordon,
V.P. and Chief Legal Counsel -
Lewis Shuster,
Director -
Plc Gsk,
10% owner -
Don M Hardison,
Director -
Holdings A/S Novo,
10% owner -
Nv Qiagen,
10% owner -
Patrick C. Roche,
SVP Research & Development -
Spaght Ventures Ii Lpfsv Ii...,
-
Donald W Grimm,
Director -
Capital Ventures Llc Senour...,
-
Tim B Johnson,
Executive Chairman -
Laurence W Lytton,
10% owner -
Thomas W. Dubensky,
Director -
Laura Lee Godlewski,
SVP Finance & Administration